FDA Grants Breakthrough Therapy Designation to Larimar's Nomlabofusp for Friedreich’s Ataxia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy LRMR?
Source: stocktwits
- Therapeutic Breakthrough: Larimar Therapeutics announced that its FXN protein replacement therapy, nomlabofusp, has received Breakthrough Therapy Designation from the FDA, aimed at treating Friedreich’s Ataxia, marking a significant advancement in rare disease treatment.
- Clinical Data Support: Preliminary findings indicate that nomlabofusp increased FXN levels in patients' skin to levels seen in asymptomatic carriers, with improvements across four key clinical measures after one year of treatment, suggesting the therapy could slow or reverse disease progression.
- FDA Endorsement of New Endpoint: The FDA agreed to recognize skin FXN as a novel surrogate endpoint reasonably likely to predict clinical benefit, supporting the planned Biologics License Application (BLA) submission targeted for June 2026, paving the way for market entry.
- Positive Market Reaction: Following the FDA's decision, Larimar's stock surged over 30% in premarket trading, while retail sentiment shifted from 'bearish' to 'extremely bullish', reflecting strong market confidence in the therapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LRMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LRMR
Wall Street analysts forecast LRMR stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.510
Low
21.00
Averages
21.50
High
22.00
Current: 5.510
Low
21.00
Averages
21.50
High
22.00
About LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Larimar Therapeutics Prices Upsized Public Offering of 20 Million Shares
- Offering Size: Larimar Therapeutics has priced its upsized public offering of 20 million shares at $5 per share, expecting total gross proceeds of $100 million, which will fund the development of its lead candidate.
- Stock Price Reaction: Following the announcement, LRMR's stock fell by 10.92% to $5.30, indicating a negative market reaction to the offering, with the stock trading between $1.61 and $6.42 over the past year.
- Use of Proceeds: The net proceeds from the offering will support the development of Nomlabofusp for Friedreich's ataxia, as well as general working capital, including research and development and commercialization expenses.
- Underwriting Details: J.P. Morgan and Guggenheim Securities are acting as joint bookrunning managers for the offering, and Larimar has granted underwriters a 30-day option to purchase an additional 3 million shares at the public offering price, enhancing market liquidity.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
Larimar Therapeutics Prices Upsized Public Offering of 20M Shares at $5.00 Each
- Offering Pricing: Larimar Therapeutics announced an upsized public offering of 20 million shares priced at $5.00 each, expecting to raise approximately $100 million before fees and expenses, indicating the company's strong capital market capabilities.
- Underwriter Option: The company granted underwriters a 30-day option to purchase up to 3 million additional shares at the same price, a strategy that could further enhance market demand for its stock.
- Use of Proceeds: Larimar plans to utilize the net proceeds from the offering to support the development of nomlabofusp and for working capital and general corporate purposes, including research and development and commercialization expenses, demonstrating its focus on future product development.
- Market Reaction: Following the announcement of the offering, LRMR shares fell 4.2% in premarket trading to $5.70, reflecting the market's short-term response and cautious investor sentiment regarding the offering.
See More
Wall Street Opens Cautiously Amid China Market Concerns
- Cautious Market Sentiment: Despite Nvidia's strong earnings report, Wall Street traders are cautious ahead of the open due to concerns over its revenue from China, with Nasdaq futures down 0.1% and Dow futures down 0.2%.
- Merger Developments in Focus: Investors are closely watching Warner Bros. Discovery's upcoming earnings report, while speculation arises that Netflix may abandon its bid for the company, with its co-CEO heading to the White House to discuss regulatory issues, highlighting the market's keen interest in merger dynamics.
- Software Giants' Guidance Miss: Salesforce's fiscal 2027 revenue guidance fell short of Wall Street expectations despite a strong Q4 earnings report, negatively impacting investor sentiment and leading to a decline in confidence in the software sector.
- Monitoring Economic Data: Investors will be attentive to the weekly jobless claims data set to be released at 8:30 a.m. ET, along with Federal Reserve Vice Chair Michelle Bowman's testimony before Congress, which could influence market perceptions of the economic outlook.
See More
Larimar Therapeutics Prices $100 Million Stock Offering Following FDA Breakthrough Designation
- Upsized Stock Offering: Following a record 61% surge on Wednesday, Larimar Therapeutics priced an upsized $100 million stock offering, issuing 20 million shares at $5 each, with proceeds aimed at supporting the development of Nomlabofusp and general corporate purposes, expected to close on Thursday.
- FDA Breakthrough Designation: The FDA granted Breakthrough Therapy Designation to Larimar's Nomlabofusp for treating Friedreich's ataxia, based on preliminary data showing significant increases in frataxin levels in patients, indicating potential for substantial improvement over existing therapies.
- BLA Submission Timeline: Larimar is on track to submit a Biologics License Application (BLA) in June, with topline data expected in Q2 to support the filing, and plans for a global Phase 3 study initiation in mid-2026, targeting a U.S. launch in the first half of 2027.
- Extremely Bullish Market Sentiment: Retail sentiment for LRMR on Stocktwits is described as 'extremely bullish', with users expressing confidence in the stock reaching $15-20 soon, reflecting strong market expectations for Larimar's future growth and drug approval prospects.
See More
Larimar Therapeutics Prices Upsized Public Offering
- Upsized Offering: Larimar Therapeutics announced the pricing of 20 million shares at $5.00 each, aiming for gross proceeds of $100 million, reflecting strong market demand for its rare disease treatments.
- Underwriter Selection: J.P. Morgan and Guggenheim Securities serve as joint bookrunning managers, with LifeSci Capital and William Blair as bookrunners, ensuring professionalism and market reach for the offering.
- Clear Use of Proceeds: The company intends to utilize the net proceeds for the development of nomlabofusp and general corporate purposes, including R&D and commercialization expenses, indicating confidence in future product prospects and strategic positioning.
- Regulatory Compliance: The offering is conducted under a shelf registration statement on Form S-3 effective since May 24, 2024, ensuring compliance and providing transparent information channels for investors, thereby enhancing market trust.
See More
Larimar Therapeutics Prices Upsized Public Offering of 20 Million Shares
- Offering Size: Larimar Therapeutics has priced its upsized public offering of 20 million shares at $5 per share, expecting total gross proceeds of $100 million, which will fund the development of its lead candidate.
- Stock Price Reaction: Following the announcement, LRMR's stock fell by 10.92% to $5.30, indicating a negative market reaction to the offering, with the stock trading between $1.61 and $6.42 over the past year.
- Use of Proceeds: The net proceeds from the offering will support the development of Nomlabofusp for Friedreich's ataxia, as well as general working capital, including research and development and commercialization expenses.
- Underwriting Details: J.P. Morgan and Guggenheim Securities are acting as joint bookrunning managers for the offering, and Larimar has granted underwriters a 30-day option to purchase an additional 3 million shares at the public offering price, enhancing market liquidity.
See More
Marriott Vacations Reports Strong Q4, Shares Surge
- Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
- Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
- Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.
See More
Larimar Therapeutics Prices Upsized Public Offering of 20M Shares at $5.00 Each
- Offering Pricing: Larimar Therapeutics announced an upsized public offering of 20 million shares priced at $5.00 each, expecting to raise approximately $100 million before fees and expenses, indicating the company's strong capital market capabilities.
- Underwriter Option: The company granted underwriters a 30-day option to purchase up to 3 million additional shares at the same price, a strategy that could further enhance market demand for its stock.
- Use of Proceeds: Larimar plans to utilize the net proceeds from the offering to support the development of nomlabofusp and for working capital and general corporate purposes, including research and development and commercialization expenses, demonstrating its focus on future product development.
- Market Reaction: Following the announcement of the offering, LRMR shares fell 4.2% in premarket trading to $5.70, reflecting the market's short-term response and cautious investor sentiment regarding the offering.
See More
Wall Street Opens Cautiously Amid China Market Concerns
- Cautious Market Sentiment: Despite Nvidia's strong earnings report, Wall Street traders are cautious ahead of the open due to concerns over its revenue from China, with Nasdaq futures down 0.1% and Dow futures down 0.2%.
- Merger Developments in Focus: Investors are closely watching Warner Bros. Discovery's upcoming earnings report, while speculation arises that Netflix may abandon its bid for the company, with its co-CEO heading to the White House to discuss regulatory issues, highlighting the market's keen interest in merger dynamics.
- Software Giants' Guidance Miss: Salesforce's fiscal 2027 revenue guidance fell short of Wall Street expectations despite a strong Q4 earnings report, negatively impacting investor sentiment and leading to a decline in confidence in the software sector.
- Monitoring Economic Data: Investors will be attentive to the weekly jobless claims data set to be released at 8:30 a.m. ET, along with Federal Reserve Vice Chair Michelle Bowman's testimony before Congress, which could influence market perceptions of the economic outlook.
See More
Larimar Therapeutics Prices $100 Million Stock Offering Following FDA Breakthrough Designation
- Upsized Stock Offering: Following a record 61% surge on Wednesday, Larimar Therapeutics priced an upsized $100 million stock offering, issuing 20 million shares at $5 each, with proceeds aimed at supporting the development of Nomlabofusp and general corporate purposes, expected to close on Thursday.
- FDA Breakthrough Designation: The FDA granted Breakthrough Therapy Designation to Larimar's Nomlabofusp for treating Friedreich's ataxia, based on preliminary data showing significant increases in frataxin levels in patients, indicating potential for substantial improvement over existing therapies.
- BLA Submission Timeline: Larimar is on track to submit a Biologics License Application (BLA) in June, with topline data expected in Q2 to support the filing, and plans for a global Phase 3 study initiation in mid-2026, targeting a U.S. launch in the first half of 2027.
- Extremely Bullish Market Sentiment: Retail sentiment for LRMR on Stocktwits is described as 'extremely bullish', with users expressing confidence in the stock reaching $15-20 soon, reflecting strong market expectations for Larimar's future growth and drug approval prospects.
See More
Larimar Therapeutics Prices Upsized Public Offering
- Upsized Offering: Larimar Therapeutics announced the pricing of 20 million shares at $5.00 each, aiming for gross proceeds of $100 million, reflecting strong market demand for its rare disease treatments.
- Underwriter Selection: J.P. Morgan and Guggenheim Securities serve as joint bookrunning managers, with LifeSci Capital and William Blair as bookrunners, ensuring professionalism and market reach for the offering.
- Clear Use of Proceeds: The company intends to utilize the net proceeds for the development of nomlabofusp and general corporate purposes, including R&D and commercialization expenses, indicating confidence in future product prospects and strategic positioning.
- Regulatory Compliance: The offering is conducted under a shelf registration statement on Form S-3 effective since May 24, 2024, ensuring compliance and providing transparent information channels for investors, thereby enhancing market trust.
See More
